Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -28.81
- Piotroski Score 0.00
- Grade Market Perform
- Symbol (CALA)
- Company Calithera Biosciences, Inc.
- Price $0.01
- Changes Percentage (0%)
- Change -$0
- Day Low $0.01
- Day High $0.01
- Year High $0.12
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/22/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$7.94
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $-18,866,000
Income Statement
Quarterly
Annual
Latest News of CALA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The west's reckless escalation of the war in Ukraine will cause more suffering, for no strategic gain | Simon Jenkins
Putin, an isolated dictator, warns of nuclear response as UK and US missiles hit Russia amid Ukraine conflict. The escalation risks a brutal Moscow retaliation. Western actions have only emboldened Pu...
By The Guardian | 1 day ago -
Sydney trains to shut down for four days as union action escalates
Industrial action may halt Sydney's train network for days due to a dispute between the NSW government and the Rail, Tram, and Bus Union. The shutdown will affect over a million commuters, with replac...
By The Guardian | 4 days ago -
Ukraine war live: Biden trying to escalate situation 'to the maximum' with missile decision, Russian lawmaker says
Russian lawmaker Maria Butina warned that allowing Ukraine to use US-made weapons to strike deep into Russia could lead to World War Three. She expressed hope that former President Donald Trump would ...
By The Guardian | 4 days ago
